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Available online 8 February 2016Biological measures of aging are important for understanding the health of an aging population, with epigenetics
particularly promising. Previous studies found that tumor tissue is epigenetically older than its donors are
chronologically. We examined whether blood Δage (the discrepancy between epigenetic and chronological
ages) can predict cancer incidence or mortality, thus assessing its potential as a cancer biomarker. In a prospec-
tive cohort, Δage and its rate of change over time were calculated in 834 blood leukocyte samples collected from
442 participants free of cancer at blood draw. About 3–5 years before cancer onset or death, Δage was associated
with cancer risks in a dose-responsive manner (P= 0.02) and a one-year increase in Δage was associated with
cancer incidence (HR: 1.06, 95% CI: 1.02–1.10) and mortality (HR: 1.17, 95% CI: 1.07–1.28). Participants with
smaller Δage and decelerated epigenetic aging over time had the lowest risks of cancer incidence (P = 0.003)
andmortality (P=0.02).Δagewas associatedwith cancer incidence in a ‘J-shaped’manner for subjects examined
pre-2003, and with cancer mortality in a time-varying manner. We conclude that blood epigenetic age may
mirror epigenetic abnormalities related to cancer development, potentially serving as a minimally invasive
biomarker for cancer early detection.





As the population continues to age in the coming decades, the need
for biological measures of age and more precise screening tests for
age-related diseases will become increasingly urgent. Genetic and
epigenetic studies have added to the potential clinical utility of this
subject area, with researchers identifying elements associated with
age-related processes (e.g., telomeres) that nonetheless have unveriﬁed
predictive power in human populations (Brooks-Wilson, 2013).
Epigenetics serves as an intersection between genetic andtive Medicine, Northwestern
IL 60611, USA.
. This is an open access article underenvironmental risk factors for aging processes and age-related diseases,
holding great promise for constructing biological agemeasures thatwill
provide clinical diagnostic tools for aging-related diseases such as can-
cer. Blood-based epigenetic markers are particularly well-suited to
these purposes due to their minimally invasive method of collection
and cost-effectiveness on the population scale.
Epigenetic age is a recently developed algorithm that uses DNA
methylation measurements to describe biological age at the level of
human tissues, cells, and organs (Hannum et al., 2013; Horvath, 2013;
Weidner et al., 2014). Epigenetic age does not always parallel chrono-
logical age, particularly in tumor samples (Hannum et al., 2013;
Horvath, 2013), a discrepancy we refer to here as Δage. Furthermore,
since the methods for measuring epigenetic age incorporate loci in
pathways related to both cancer development and aging in general
(e.g., DNA damage, cellular proliferation, and oxidative stress)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
69Y. Zheng et al. / EBioMedicine 5 (2016) 68–73(Hannum et al., 2013; Horvath, 2013), it is highly possible that Δage can
be a predictive biomarker for cancer risk, metastasis, and mortality in
addition to serving as an indicator of aging. With further study and
reﬁnement, the concept of epigenetic agemay also be useful for improv-
ing our understanding of mechanisms by which age and cancer are re-
lated. However, no longitudinal analysis has yet evaluated how blood
epigenetic age changes over time prior to cancer diagnosis or cancer-
related death, and whether blood Δage can predict future risk of cancer
incidence and mortality.
Our objective is to assess whether white blood cell (WBC) Δage
can predict cancer incidence and mortality, and to evaluate these
predictions over time. Wewill achieve our goals by comparingmultiple
estimates of Δage obtained using blood DNA samples collected prior to
cancer incidence and death in: 1) individuals who developed cancer
relative to cancer-free individuals and 2) individuals who died of cancer
relative to both cancer survivors and cancer-free individuals.
2. Materials and Methods
2.1. Study Design and Participants
The U.S. Department of Veterans Affairs' Normative Aging Study
(NAS) is a longitudinal cohort established in 1963 (Bell et al., 1966).
Between March 1999 and December 2013, 802 out of 829 (96.7%) of
active participants agreed to donate blood, 686ofwhomwere randomly
selected and proﬁled using the Illumina 450 K BeadChip array at up to
three follow-up visits separated by median time intervals of 3.5 years
(IQR 3.1–5.7) (Supplementary material, Fig. S1). We excluded 18
participants who were non-White or had missing information on
race to minimize potential confounding effects of genetic ancestry, 182
participants who had been diagnosed with malignant cancer prior to
the ﬁrst blood draw, and 44 participants who had been diagnosed
with neoplasms of uncertain behavior, leaving a total of 442 participants
for analysis. Cancer diagnoses and comorbidities (prevalent diabetes,
hypertension, coronary artery disease, and stroke) were obtained from
questionnaires and conﬁrmed via blinded medical record review.
Ofﬁcial death certiﬁcates were reviewed by a physician, and all contrib-
uting causes coded by an experienced research nurse. Telomere length
was measured using quantitative real-time polymerase chain reaction
and reported in relative units, as previously described (Hou et al.,
2015). Of the 442 participants free of cancer at ﬁrst blood draw,
132 developed cancer during follow-up (38 prostate, 50 skin, 44
other) and 34 died from cancer (4 prostate, 2 skin, 28 other). The
remaining 98 participants died from non-cancer causes or were
still alive as of latest follow-up, and are deﬁned as cancer survivors
for our analysis (Supplementary material, Fig. S2). Median follow-up
time (from ﬁrst blood draw) to cancer incidence or censoring was
10.1 years (IQR 5.8–12.7) and 11.9 years (IQR 8.8–13.0) to cancer
mortality or censoring. This study was approved by the Institutional
Review Boards of all participating institutions, and all participants
provided written consent.
2.2. Illumina Inﬁnium HumanMethylation450 BeadChip DNA Methylation
Proﬁling
DNAwas extracted from the buffy coat using the QIAampDNABlood
Kit (QIAGEN, Valencia, CA, USA). A total of 500 ng of DNA was used to
perform bisulﬁte conversion using the EZ-96 DNA Methylation Kit
(Zymo Research, Orange, CA, USA). To limit chip and plate effects a
two stage, age-stratiﬁed algorithm was used to randomize samples
and ensure similar age distributions across chips and plates. We
randomized 12 samples (sampled across all age quartiles) per chip,
and then randomized chips to plates. Quality control analysis was
performed to remove samples where N1% of probes had a detection
P N 0.05. The remaining samples were preprocessed using Illumina-
type background correction without normalization as re-implementedin the Bioconductor minﬁ package and used to generate beta values
(Aryee et al., 2014). The working set included all 485,512 CpG and
CpH probes for epigenetic age estimation.
2.3. Epigenetic Age and Δage Calculation
We estimated epigenetic age as measured by Hannum's 71-CpG
method using Horvath's online calculator (http://labs.genetics.ucla.
edu/horvath/dnamage/), which incorporates both previously-
published methods (Hannum et al., 2013; Horvath, 2013) based on
prior work showing superior predictive accuracy in blood (Marioni
et al., 2015). We selected Hannum's method because the model
was trained using blood samples and it yielded accurate and longitudi-
nally stable epigenetic age estimation using our blood-based methyla-
tion data (Supplementary material, Fig. S3). To remove potential
confounding due to alterations in WBC composition with age (Marioni
et al., 2015) and naïve T cell changes due to thymic involution (Taub
and Longo, 2005), cell abundances were estimated via previously
published methods (Horvath, 2013; Houseman et al., 2012). We then
used the residuals from a linear regression of epigenetic age on
chronological age and these cell type abundances to calculate Δage
(with Δage N 0 indicating epigenetic age older than chronological
age), resulting in a construct less sensitive to normal age-related
changes in WBC composition and immunosenescence (Supplementary
material, Fig. S4).
2.4. Statistical Analysis
We performed descriptive analyses of participant characteristics
(including epigenetic age and Δage) at ﬁrst blood draw using linear
mixed-effect models. We then expanded these descriptive analyses to
assess dose–response via a multivariable linear mixed-effect model
comparing Δage across samples (estimated by least squares means) in
participants who died from cancer, cancer survivors, and cancer-free
participants. Next, we used Random Matrix Theory (Plerou et al.,
2002) available in R package isva (Teschendorff et al., 2011) to deter-
mine that there were two signiﬁcant components of variation in
our data. We made a heat map (Supplementary material, Fig. S5) of
P-values matrix of associations between the signiﬁcant components
and: biological (Houseman's six blood cell type proportions;
Houseman et al., 2012), epidemiological (the 11 covariates we
considered) and technical factors (plate number, chip number, row
number and column number of the chip). We found that the compo-
nents were strongly associated with biological and technical factors,
but not epidemiological factors. Therefore, all subsequent models
adjusted for the top two principle components computed from the
450 K array data to account for batch effects and residual biological
confounding. We included the third top PC to better capture latent
population stratiﬁcation of the data (Barﬁeld et al., 2014).
Prior to running our survival analyses, we evaluated the proportion-
al hazards assumption for both cancer incidence and mortality by
plotting Schoenfeld residuals over time. Although the hazards for cancer
incidence were proportional across all follow-up time, the mortality
analysis violated the proportional hazards assumption with marginal
statistical signiﬁcance (P = 0.04; data available upon request). There-
fore, our subsequent analyses examined Δage and cancer both across
all follow-up visits and stratiﬁed by year of blood DNA collection. We
selected a stratiﬁcation point of January 1st, 2003 as 1) it separated
two data collection ‘cycles’ in the NAS rotation protocol (Supplementary
material, Fig. S1), and 2) the resulting subgroups were of similar
size. Subsequent testing of the proportional hazards assumption
within these strata revealed no violations for either cancer incidence
or mortality.
We plotted KM curves, comparing participants epigenetically older
than their chronological age (Δage N 0) to those epigenetically younger
than their chronological age (Δage ≤ 0) using log-rank tests. Next, we
Table 1
Characteristics of participants cancer free at ﬁrst blood draw.
Characteristics N = 442 (Obs. = 834)
Chronological age, mean (SD), y 71.7 (6.7)
Epigenetic age, mean (SD), y 72.1 (8.5)
Δage, mean (SD), y −0.1 (4.2)
BMI, No. (%)
Normal (b25.0 kg/m2) 79 (17.9)
Overweight (25.0 to b30.0 kg/m2) 244 (55.2)
Obese (≥30.0 kg/m2) 119 (26.9)
Max. education, No. (%)a
b13 y 113 (25.6)
13 to 16 y 220 (49.8)
N16 y 108 (24.4)
Never smoker, No. (%) 131 (29.6)
Pack–years of smoking, No. (%)
0 131 (29.6)
1 to b30 174 (39.4)
≥30 137 (31.0)
Alcohol intake less than two drinks, No. (%) 367 (83.0)
Telomere length, mean (SD), relative unitsb 1.3 (0.5)
Diabetes prevalence, No. (%) 73 (16.5)
Hypertension prevalence, No. (%) 300 (67.9)
CHD prevalence, No. (%) 124 (28.1)
Stroke prevalence, No. (%) 23 (5.2)
Abbreviations: BMI, body mass index; CHD, coronary artery disease.
a One missing (0.2%) value in max year of education.
b Telomere length was missing for fourteen (3.2%) observations at ﬁrst blood draw and
a total of 134 (16.1%) observations.
Fig. 1.Dose–response analysis ofΔage by cancer status. Least squares means ofΔage across
cancer status groups were estimated by linear mixed-effect models to account for
repeated measures. We compared participants who died from cancer, cancer survivors,
and cancer-free participants and found that severity of cancer outcome increased as Δage
increased. Error bars represent standard errors.
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associations between Δage and times to cancer diagnosis and death.
We investigated potential nonlinearity of these associations using
pointwise HR curves (Meira-Machado et al., 2013) and generalized ad-
ditive Coxmodels using penalized splines (Hastie and Tibshirani, 1995).
Finally, using the 299 participants with two or more samples, we com-
puted the slope of Δage over time and categorized these participants
as having accelerated (Δage slope N 0) or decelerated (Δage slope ≤ 0)
epigenetic aging over time. We then used a second set of KM survival
curves and log-rank tests to analyze the relationship between Δage, epi-
genetic aging over time, and cancer.
Our multivariable models additionally adjusted for chronological
age at ﬁrst blood draw, BMI, education, smoking status, pack-years of
smoking, and alcohol consumption. One participant with missing data
on education was excluded from multivariable analysis. Five other
variables (telomere length and presence of four comorbidities) were
examined in separate sensitivity analyses of our Cox models. The
inclusion of these variables did not substantively affect our estimates
(Supplementary material, Table S1) and they were therefore excluded
due to having high proportions of missing data. We conducted all
analyses using R v3.0.2, two-sided tests, and a statistical signiﬁcance
threshold of P= 0.05.
2.5. Data Availability




This study was funded by the Epidemiology Research and
Information Center, U.S. Department of Veterans Affairs; NIEHS
R01-ES015172. Additional funding support was provided by the
Northwestern University Robert H. Lurie Comprehensive Cancer
Center Rosenberg Research Fund. The funding institutions had no
role in the study design, data collection or analysis, interpretation
of ﬁndings, manuscript preparation, or decision to pursue peer-
review publication. No author has been paid to write this article by
a pharmaceutical company or other agency.
3. Results
Characteristics of participants at ﬁrst blood draw were similar
to previous reports (Hou et al., 2015; Zhu et al., 2011), indicating suc-
cessful randomization. No participant characteristics were associated
with Δage (Supplementary material, Table S2). Mean epigenetic age
was almost identical to chronological age but with greater variance
(Table 1). There were 422 observations of 370 participants during the
ﬁrst half of the follow-up period (pre-2003) and 412 observations of
306 participants during the second half (2003–2013). In the pre-2003
stratum the median times to cancer diagnosis and death were 5.1 (IQR
(interquartile range) 2.7–8.6) and 7.0 years (IQR5.3–10.1), respectively.
In the 2003–2013 stratum the median times to cancer diagnosis and
death were 3.0 (IQR 0.6–5.7) and 4.6 years (IQR 2.4–7.0), respectively.
The pre-2003 analysis included 370 and 52 samples from participants
at their ﬁrst and second time-point of measures, respectively. The
2003–2013 analysis included 72, 247, and 93 samples from participants
at their ﬁrst, second, and third time-point of measures, respectively.
Using data gathered from 2003 to 2013, our dose–response analysis
identiﬁed greater Δage in cancer survivors and participants who
died from cancer (Δage = 0.5 and 2.2 years, respectively) relative to
cancer-free participants (Δage = −0.4 years, test for trend P = 0.02)
(Fig. 1); Kaplan–Meier (KM) curves comparing Δage also suggested
participants with greater Δage had a higher risk of cancer incidence
(log-rank P = 0.002) and cancer mortality (log-rank P = 0.04)(Supplementary material, Fig. S6). We observed weaker, non-signiﬁcant
results in analyses using samples before 2003 and using all samples
combined.
Adjusted for covariates, the 2003–2013 time-dependent Coxmodels
revealed that each one-year increase inΔagewas associatedwith greater
risks of cancer incidence (HR: 1.06, 95% CI: 1.02–1.10), and mortality
(HR: 1.17, 95% CI: 1.07–1.28). We found no associations between Δage
and cancer risk in either all samples combined or the pre-2003 samples
(Table 2). Point-wise HR curves of Δage illustrated a J-shaped relation-
ship in cancer incidence for samples taken pre-2003 (P= 0.03 for test
of nonlinearity) (Fig. 2A). The risk of cancer mortality increased linearly
with Δage in the 2003–2013 samples, but this association was substan-
tially weaker for pre-2003 samples (Fig. 2B). KM survival curves exam-
ining Δage rate of change over time showed that participants who were
epigenetically young relative to their chronological age (Δage ≤ 0) and
had decelerated or stable epigenetic aging over time (Δage slope ≤ 0)
Table 2
Hazard ratios per each one-year increase in Δage.
N (Obs.) Cancer incidence Cancer mortality
HR (95% CI) P value HR (95% CI) P value
All samples
Crude modela 442 (834) 1.03 (1.00–1.06) 0.04 1.05 (1.00–1.12) 0.07
Adjusted modelb 441 (833) 1.03 (1.00–1.06) 0.06 1.05 (0.99–1.12) 0.08
Pre-2003 samples
Crude modela 370 (422) 1.03 (0.99–1.06) 0.14 1.04 (0.98–1.11) 0.17
Adjusted modelb 370 (422) 1.02 (0.99–1.06) 0.20 1.05 (0.99–1.12) 0.11
2003–2013 samples
Crude modela 306 (412) 1.06 (1.02–1.10) 0.003 1.12 (1.03–1.21) 0.007
Adjusted modelb 305 (411) 1.06 (1.02–1.10) 0.004 1.17 (1.07–1.28) 0.001
a Crude model was adjusted for the top three principal components only.
b Additionally adjusted for chronological age at ﬁrst blood draw, BMI, education, smoking, pack–years, and alcohol consumption.
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and P= 0.02, respectively, Fig. 3).
4. Discussion
Our results indicate a strong, possibly dose-responsive, relationship
between Δage and cancer incidence and mortality that is independent
of telomere shortening and several epidemiological risk factors for
cancer. The relationships between Δage and cancer were strongest in
DNA samples collected within three to ﬁve years of a cancer event and
among participants with accelerated epigenetic aging over time. These
ﬁndings, coupled with our spline showing a nonlinear, J-shaped
relationship between Δage and cancer incidence suggest a dynamic
and complex relationship between Δage and cancer over the long term.
A diagnostic test to detect an individual's discrepancies between
epigenetic and chronological age could therefore prove useful for cancer
risk and prognosis assessment.
Epigenetic modiﬁcations are potentially central to biological
processes of aging (Ben-Avraham et al., 2012), and both global
(Ben-Avraham et al., 2012) and gene-speciﬁc methylation can be al-
tered substantially by the aging process (Gravina and Vijg, 2010).
While the accumulation of epigenetic changes is a hallmark of
cancer, few studies have prospectively examined the potential of
age-related epigenetic changes to predict cancer. The observed
association between Δage and cancer was independent of chronolog-
ical age, telomere length, and several known lifestyle risk factors for
cancer (e.g., body mass index (BMI), and smoking). The method for
calculating epigenetic age in our analysis combines age-dependent
CpG sites enriched in pathways that are also involved in carcinogen-
esis (Hannum et al., 2013; Horvath, 2013), and our ﬁndings indicate
that this may be a viable strategy for developing predictiveFig. 2. Point-wise hazard ratio curves between Δage and risk of cancer. Risk of cancer incidence
pre-2003 (black dash line) and 2003–2013 (black solid line) strata. Log-transformed HR = 0 (
were tested using spline analysis. Only signiﬁcant relationships were noted in the ﬁgure.biomarkers of cancer. In addition, our sensitivity analyses found
that the association between Δage and cancer is independent of both
telomere length and other comorbidities, suggesting Δage as a speciﬁc
cancer biomarker as well as the possibility that Δage reﬂects molecular-
level aging or carcinogenic processes that are not captured by telomere
measurements.
Our ﬁndings are intriguing and biologically plausible. A recentmeta-
analysis of four large longitudinal cohorts revealed that Δage measured
in blood DNA correlates well with all-cause mortality rates and is inde-
pendent of health, lifestyle, and genetic factors (Marioni et al., 2015).
Another recent study of lung cancer found and even stronger rela-
tionship between blood epigenetic age and cancer mortality using
Horvath's method (Levine et al., 2015). While blood epigenetic age
is already being studied in HIV-1 patients with clinical signs of
aging (Horvath and Levine, 2015), it may be even more valuable in
studies of cancer. WBC play an important role in carcinogenesis via
inﬂammatory response and pro-apoptotic processes (Ichikawa
et al., 2011; Schnekenburger et al., 2008), both of which also affect
epigenetic age. The discrepancy between epigenetic and chronolog-
ical age, i.e. Δage, has also been associated with cancer prognosis in
tumor tissue data from The Cancer Genome Atlas (Lehne et al.,
2015). However, sampling different tissues is not feasible for cancer
screening at the population level, both for practical reasons and
because different cancers can have tissue-speciﬁc, differential, and
even opposing effects on epigenetic age (Horvath, 2013; Horvath,
2015), Therefore, our ﬁnding of the predictive value of blood-based
epigenetic age for cancer risk and mortality is particularly provoca-
tive and potentially valuable for use as a screening tool for cancer
as it can offer more stable and reliable predictions (Horvath, 2013).
The method used in our study for measuring epigenetic age was
based on a model trained on genome-wide DNAmethylation extracted(A) and mortality (B) represented by log-transformed HRwere plotted against Δage in the
gray solid line) is equivalent to hazard ratio = 1. Both linear and non-linear relationships
Fig. 3.Kaplan–Meier survival curves comparing risk of cancer grouped byΔage and its rate of change. A: cancer incidence; B: cancermortality.Δage slopewas calculated for each participant
with two or more visits to represent the Δage rate of change. KM survival curves were then plotted among each of the combination of the binary Δage and its rate of change. Young:
epigenetically young (Δage ≤ 0); old: epigenetically old (Δage N 0); decelerated: decelerated or stable epigenetic aging over time (Δage slope ≤ 0); accelerated: accelerated epigenetic
aging over time (Δage slope N 0).
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from extracted WBC, epigenetic age measured in our study could be a
proxy measure for the immune response to cancer initiation and pro-
gression, potentially explaining the complex, nonlinear, and time-
dependent relationships between Δage, cancer incidence, and cancer
mortality we observed. It is well-known that thymic involution with
aging can result in diminishing numbers of naïve T cells (Taub and
Longo, 2005). Our data also suggested that increasing epigenetic age
was associated with loss of naïve CD8+ T cells (r =−0.24, P b 0.001,
Supplementary material, Fig. S7). After removing the confounding ef-
fects of chronological age and immunosenescence usingΔage, our spline
plots showed that the risk of developing cancer over time is minimized
at Δage = 0, with a more linear risk proﬁle emerging 3–5 years prior to
diagnosis (Fig. 2). This may reﬂect the initial anti-inﬂammatory and
pro-apoptotic response by the body to early carcinogenesis, which trig-
gers increased WBC production that successfully (albeit temporarily)
represses cancer. As the cancer eventually adapts to such immune
responses they become less effective, resulting in the J-shaped curve
evident in our spline plot. Thus, epigenetic age substantially ‘younger’
than chronological age (negative Δage) may be a biomarker of the initial
response to a developing cancer before it is detectable through standard
diagnostic means. The ﬁndings of our Kaplan–Meier curve relating any
disruption in the normal epigenetic aging observed in healthy subjects
(i.e. either higherΔage or accelerated epigenetic aging over time) to can-
cer incidence and mortality are also consistent with this hypothesis
(Fig. 3, Supplementary material, Fig. S6). As we continue to accrue
follow-up data for this cohort, we can assess whether this suggestion
is accurate by comparing health outcomes for epigenetically ‘young’ to
epigenetically ‘old’ subjects over time. These ﬁndings should also be
veriﬁed in other, larger datasets.
The observed dynamics are also reﬂected in the straightforward
Δage–mortality relationship. Delays between cancer diagnosis and
death may allow time for normal thymic involution and other age-
related immune deterioration processes to reassert themselves, after
the initial response to cancer. This would effectively allow epigenetic
age to ‘catch up’ to chronological age and produce the observed linear
relationship withmortality. Alternatively, our ﬁndings related to cancer
mortality could also be reﬂective ofmetastasis-induced changes inWBC
epigenetic proﬁles. Longer follow-up in larger groups will be necessary
to conﬁrm these hypotheses, but if conﬁrmed, they suggest that Δage
would be best utilized as a biomarker of early immune response to
carcinogenic processes, with any perturbations of epigenetic agerelative to chronological age serving as a potentially useful indicator
for use in mass screenings for cancer.
The longitudinal nature of our study enabled us to establish tempo-
ral associations between Δage and cancer risk. Our sample size limited
our ability to conduct meaningful analyses of cancer subtypes, thus
caution should be exercised in interpreting our results. However,
while different cancers are biologically distinct from one another
blood-based Δage may not be cancer-type-speciﬁc. As carcinogenesis
usually alters methylation of WBC through inﬂammation and immune
senescence pathways common to most cancer types (Ponnappan and
Ponnappan, 2011; Li et al., 2012), epigenetic age acceleration in blood
DNA may be a useful biomarker for many (if not all) types of cancer.
Therefore, pooling multiple different cancers is biologically plausible
for purposes of examining Δage in blood. Additional studies with
longer follow-up are needed to conﬁrm this, and to verify the dynamic,
nonlinear, and time-dependent relationship between Δage and cancer.
Epigenetic age is comparable to chronological age among cancer-
free participants. Those with older epigenetic age relative to their
chronological age have an elevated risk of cancer events within three
to ﬁve years. Our study provides insight into using blood-based epige-
netic age as a potential biomarker for cancer early detection. It may
also inform future studies of the effects of aging on cancer and potential-
ly other diseases. Expanding this research to additional time points
would help determine when in the course of the disease cancer-
related changes in epigenetic age occur, and the extent to which Δage
is different across individuals and cancers.Author Contributions
Yinan Zheng, Brian Joyce, and Elena Colicino had full access to all of
the data in the study and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Study concept and design: Zheng, Joyce, Hou.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Zheng, Joyce, Hou.
Critical revision of themanuscript for important intellectual content:
All authors.
Statistical analysis: Zheng.
Obtained funding: Hou, Baccarelli, Schwartz.
Administrative, technical, or material support: Jafari.
Study supervision: Hou.
73Y. Zheng et al. / EBioMedicine 5 (2016) 68–73Acknowledgments
The authors thank Alan Aalsburg, Genomics Core Facility,
Northwestern University Feinberg School of Medicine, for methylation
proﬁling lab work and raw data generation.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.02.008.
References
Aryee, M.J., Jaffe, A.E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A.P., Hansen, K.D.,
Irizarry, R.A., 2014. Minﬁ: a ﬂexible and comprehensive Bioconductor package for
the analysis of Inﬁnium DNA methylation microarrays. Bioinformatics 30 (10),
1363–1369. http://dx.doi.org/10.1093/bioinformatics/btu049 (PubMed PMID:
24478339; PubMed Central PMCID: PMC4016708).
Barﬁeld, R.T., Almli, L.M., Kilaru, V., Smith, A.K., Mercer, K.B., Duncan, R., Klengel, T., Mehta,
D., Binder, E.B., Epstein, M.P., Ressler, K.J., Conneely, K.N., 2014. Accounting for
population stratiﬁcation in DNA methylation studies. Genet. Epidemiol. 38 (3),
231–241. http://dx.doi.org/10.1002/gepi.21789 (PubMed PMID: 24478250; PubMed
Central PMCID: PMC4090102).
Bell, B., Rose, C.L., Damon, A., 1966. The Veterans Administration longitudinal study of
healthy aging. The Gerontologist 6 (4), 179–184 (PubMed PMID: 5342911).
Ben-Avraham, D., Muzumdar, R.H., Atzmon, G., 2012. Epigenetic genome-wide association
methylation in aging and longevity. Epigenomics 4 (5), 503–509. http://dx.doi.org/10.
2217/epi.12.41 (Epub 2012/11/08, PubMed Central PMCID: PMCPMC4123813).
Brooks-Wilson, A.R., 2013. Genetics of healthy aging and longevity. Hum. Genet. 132 (12),
1323–1338 (Epub 2013/08/09. doi: 10.1007/s00439-013-1342-z; PubMed Central
PMCID: PMCPMC3898394).
Gravina, S., Vijg, J., 2010. Epigenetic factors in aging and longevity. Pﬂugers Arch. 459 (2),
247–258. http://dx.doi.org/10.1007/s00424-009-0730-7 (Epub 2009/09/22, PubMed
PMID: 19768466).
Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., Klotzle, B., Bibikova, M.,
Fan, J.B., Gao, Y., Deconde, R., Chen, M., Rajapakse, I., Friend, S., Ideker, T., Zhang, K.,
2013. Genome-wide methylation proﬁles reveal quantitative views of human aging
rates. Mol. Cell 49 (2), 359–367. http://dx.doi.org/10.1016/j.molcel.2012.10.016
(PubMed PMID: 23177740; PubMed Central PMCID: PMC3780611).
Hastie, T., Tibshirani, R., 1995. Generalized additive models for medical research. Stat.
Methods Med. Res. 4 (3), 187–196. http://dx.doi.org/10.1177/096228029500400302
(doi: citeulike-article-id:8292286).
Horvath, S., 2013. DNAmethylation age of human tissues and cell types. Genome Biol.
14 (10), R115. http://dx.doi.org/10.1186/gb-2013-14-10-r115 (PubMed PMID:
24138928; PubMed Central PMCID: PMC4015143).
Horvath, S., 2015. Erratum to: DNA methylation age of human tissues and cell types.
Genome Biol. 16, 96. http://dx.doi.org/10.1186/s13059-015-0649-6 (PubMed PMID:
25968125; PubMed Central PMCID: PMC4427927).
Horvath, S., Levine, A.J., 2015. HIV-1 infection accelerates age according to the epigenetic
clock. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiv277 (Epub 2015/05/15).
Hou, L., Joyce, B.T., Gao, T., Liu, L., Zheng, Y., Penedo, F.J., Liu, S., Zhang, W., Bergan, R., Dai,
Q., Vokonas, P., Hoxha, M., Schwartz, J., Baccarelli, A., 2015. Blood telomere length
attrition and cancer development in the normative aging study cohort. EBioMedicine
2 (6), 591–596. http://dx.doi.org/10.1016/j.ebiom.2015.04.008.
Houseman, E.A., Accomando, W.P., Koestler, D.C., Christensen, B.C., Marsit, C.J., Nelson,
H.H., Wiencke, J.K., Kelsey, K.T., 2012. DNA methylation arrays as surrogate measures
of cell mixture distribution. BMC Bioinf. 13, 86. http://dx.doi.org/10.1186/1471-2105-
13-86 (PubMed PMID: 22568884; PubMed Central PMCID: PMC3532182).Ichikawa, M., Williams, R., Wang, L., Vogl, T., Srikrishna, G., 2011. S100A8/A9 activate key
genes and pathways in colon tumor progression. Mol. Cancer Res. 9 (2), 133–148.
http://dx.doi.org/10.1158/1541-7786.mcr-10-0394 (Epub 2011/01/14, PubMed
PMID: 21228116; PubMed Central PMCID: PMCPMC3078037).
Lehne, B., Drong, A.W., Loh, M., Zhang, W., Scott, W.R., Tan, S.T., Afzal, U., Scott, J., Jarvelin,
M.R., Elliott, P., McCarthy, M.I., Kooner, J.S., Chambers, J.C., 2015. A coherent approach
for analysis of the Illumina HumanMethylation450 BeadChip improves data quality
and performance in epigenome-wide association studies. Genome Biol. 16, 37.
http://dx.doi.org/10.1186/s13059-015-0600-x (PubMed PMID: 25853392; PubMed
Central PMCID: PMCPMC4365767).
Levine, M.E., Hosgood, H.D., Chen, B., Absher, D., Assimes, T., Horvath, S., 2015. DNA
methylation age of blood predicts future onset of lung cancer in the women's health
initiative. Aging (Albany NY) 7 (9), 690–700 (PubMed PMID: 26411804; PubMed
Central PMCID: PMCPMC4600626).
Li, L., Choi, J.Y., Lee, K.M., Sung, H., Park, S.K., Oze, I., Pan, K.F., You, W.C., Chen, Y.X., Fang,
J.Y., Matsuo, K., Kim, W.H., Yuasa, Y., Kang, D., 2012. DNA methylation in peripheral
blood: a potential biomarker for cancer molecular epidemiology. J. Epidemiol. Jpn.
Epidemiol. Assoc. 22 (5), 384–394 (PubMed PMID: 22863985; PubMed Central
PMCID: PMC3798632).
Marioni, R.E., Shah, S., McRae, A.F., Chen, B.H., Colicino, E., Harris, S.E., Gibson, J., Henders,
A.K., Redmond, P., Cox, S.R., Pattie, A., Corley, J., Murphy, L., Martin, N.G., Montgomery,
G.W., Feinberg, A.P., Fallin, M., Multhaup, M.L., Jaffe, A.E., Joehanes, R., Schwartz, J.,
Just, A.C., Lunetta, K.L., Murabito, J.M., Starr, J.M., Horvath, S., Baccarelli, A.A., Levy,
D., Visscher, P.M., Wray, N.R., Deary, I.J., 2015. DNA methylation age of blood predicts
all-cause mortality in later life. Genome Biol. 16 (1), 25. http://dx.doi.org/10.
1186/s13059-015-0584-6 (PubMed PMID: 25633388; PubMed Central PMCID:
PMC4350614).
Meira-Machado, L., Cadarso-Suarez, C., Gude, F., Araujo, A., 2013. smoothHR: an R package
for pointwise nonparametric estimation of hazard ratio curves of continuous predic-
tors. Comput. Math. Methods Med. 2013, 745742. http://dx.doi.org/10.1155/2013/
745742 (PubMed PMID: 24454541; PubMed Central PMCID: PMC3876718).
Plerou, V., Gopikrishnan, P., Rosenow, B., Amaral, L.A., Guhr, T., Stanley, H.E., 2002.
Random matrix approach to cross correlations in ﬁnancial data. Phys. Rev. E Stat.
Nonlinear Soft Matter Phys. 65 (6 Pt 2), 066126. http://dx.doi.org/10.1103/
PhysRevE.65.066126 (PubMed PMID: 12188802).
Ponnappan, S., Ponnappan, U., 2011. Aging and immune function: molecular
mechanisms to interventions. Antioxid. Redox Signal. 14 (8), 1551–1585.
http://dx.doi.org/10.1089/ars.2010.3228 PubMed PMID: 20812785; PubMed
Central PMCID: PMC3061194).
Schnekenburger, J., Schick, V., Kruger, B., Manitz, M.P., Sorg, C., Nacken, W., Kerkhoff, C.,
Kahlert, A., Mayerle, J., Domschke,W., Lerch, M.M., 2008. The calcium binding protein
S100A9 is essential for pancreatic leukocyte inﬁltration and induces disruption of
cell–cell contacts. J. Cell. Physiol. 216 (2), 558–567. http://dx.doi.org/10.1002/jcp.
21433 (Epub 2008/05/03).
Taub, D.D., Longo, D.L., 2005. Insights into thymic aging and regeneration. Immunol. Rev.
205, 72–93. http://dx.doi.org/10.1111/j.0105-2896.2005.00275.x (PubMed PMID:
15882346).
Teschendorff, A.E., Zhuang, J., Widschwendter, M., 2011. Independent surrogate variable
analysis to deconvolve confounding factors in large-scale microarray proﬁling
studies. Bioinformatics 27 (11), 1496–1505. http://dx.doi.org/10.1093/bioinformatics/
btr171 (PubMed PMID: 21471010).
Weidner, C.I., Lin, Q., Koch, C.M., Eisele, L., Beier, F., Ziegler, P., Bauerschlag, D.O., Jockel,
K.H., Erbel, R., Muhleisen, T.W., Zenke, M., Brummendorf, T.H., Wagner, W., 2014.
Aging of blood can be tracked by DNA methylation changes at just three CpG sites.
Genome Biol. 15 (2), R24. http://dx.doi.org/10.1186/gb-2014-15-2-r24 (PubMed
PMID: 24490752; PubMed Central PMCID: PMC4053864).
Zhu, Z.Z., Sparrow, D., Hou, L., Tarantini, L., Bollati, V., Litonjua, A.A., Zanobetti, A., Vokonas,
P., Wright, R.O., Baccarelli, A., Schwartz, J., 2011. Repetitive element hypomethylation
in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly
individuals: the Normative Aging Study. Cancer Causes Control 22 (3), 437–447.
http://dx.doi.org/10.1007/s10552-010-9715-2 (Epub 2010/12/29. PubMed Central
PMCID: PMCPMC3752839).
